The cancer-focused Bay Area biotech CohBar is entering into a reverse merger with the privately-held biotech Morphogenesis. On Tuesday, CohBar and Morphogenesis announced the all-stock transaction. The newly combined company will operate under the name TuHURA Biosciences and trade on the Nasdaq. The deal is expected to close in the…
...